Fig 1.
A flow-chart diagram of materials and methods.
Table 1.
Pharmacokinetics/pharmacodynamics parameters.
Table 2.
Pharmacokinetics parameters.
Fig 2.
Comparisons of treatment efficacy of different proposed regimens and IC50 values with 100% of adherence in patients with resistant mefloquine.
Fig 3.
Comparisons of relative riskof different proposed regimens and IC50 values with 100% of adherence in patients with resistant mefloquine.
Fig 4.
Comparisons ofnumber-need to treat of different proposed regimens and IC50 values with 100% of adherence in patients with resistant mefloquine.
Fig 5.
Comparisons of treatment efficacy of two propose regimens (III, and IV) between 100% of adherence and 30% of adherence in patients with resistant mefloquine.
Fig 6.
Comparisons ofrelative risk of two propose regimens (III, and IV) between 100% of adherence and 30% of adherence in patients with resistant mefloquine.
Fig 7.
Comparisons of effect of initial parasites density on treatment efficacy of regimen-I (a three-day combination of artesunate-mefloquine) with different IC50 values in patients with resistant mefloquine.
Fig 8.
Comparisons ofodd ratios of regimen-I (a three-day combination of artesunate-mefloquine) with different IC50 values in patients with resistant mefloquine.
Fig 9.
Comparisons of treatment efficacy of five proposed regimens between two IC50 values in patients with sensitive mefloquine.
Table 3.
Model parameters for internal validation.